Healthcare Sales & Marketing Network News: CAP-1002

Searching News Database: CAP-1002

HSMN NewsFeed - 29 Nov 2017
Capricor Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for CAP-1002
Biopharmaceuticals FDA

HSMN NewsFeed - 4 Oct 2017
Capricor Therapeutics Presents Positive Six-Month Results in Duchenne Muscular Dystrophy at World Muscle Society International Congress
Regenerative Medicine

HSMN NewsFeed - 18 Jul 2017
Capricor Receives Rare Pediatric Disease Designation from FDA for CAP-1002 for Patients with Duchenne Muscular Dystrophy
Biopharmaceuticals FDA

HSMN NewsFeed - 12 May 2017
Capricor Therapeutics Provides Update on ALLSTAR Trial
Regenerative Medicine Cardiology

HSMN NewsFeed - 17 Feb 2017
Capricor Therapeutics Provides Update on Natriuretic Peptide Program
Biopharmaceuticals

HSMN NewsFeed - 14 Oct 2014
Capricor Therapeutics Announces Acquisition of Intellectual Property Rights to Family of Natriuretic Peptides From Medtronic, Inc.
Biopharmaceuticals Devices Cardiology Acquisitions

HSMN NewsFeed - 8 Jul 2013
Capricor and Nile Therapeutics Announce Merger Agreement
Regenerative Medicine Cardiology Mergers & Acquisitions

HSMN NewsFeed - 7 Mar 2013
Capricor, Inc. Appoints Anthony Davies, Ph.D., Chief Technology Officer
Regenerative Medicine Cardiology Personnel

HSMN NewsFeed - 9 Jul 2012
Capricor Announces FDA Approval To Initiate ALLSTAR Trial of Allogeneic Stem Cell Therapy In Patients Following Heart Attack
Regenerative Medicine Cardiology FDA

Return to NewsFeed

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.

FindReps - available on the Apple App Store for iPhone and iPad.